U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C2H6O3S2
Molecular Weight 142.197
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 2-MERCAPTOETHANESULFONIC ACID

SMILES

OS(=O)(=O)CCS

InChI

InChIKey=ZNEWHQLOPFWXOF-UHFFFAOYSA-N
InChI=1S/C2H6O3S2/c3-7(4,5)2-1-6/h6H,1-2H2,(H,3,4,5)

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c79a07d-32cc-4fe7-9a74-152c169f1c4f http://www.drugbank.ca/drugs/DB09110 https://en.wikipedia.org/wiki/Mesna

Mesna is an organosulfur compound used as an adjuvant in cancer chemotherapy involving cyclophosphamide and ifosfamide. No clinical drug interaction studies have been conducted with mesna. Mesna concentrates in the bladder where acrolein accumulates after administration of chemotherapy and through a Michael addition, forms a conjugate with acrolein and other urotoxic metabolites. This conjugation reaction inactivates the urotoxic compounds to harmless metabolites. The most common adverse reactions (> 10%) when MESNEX is given with ifosfamide are nausea, vomiting, constipation, leukopenia, fatigue, fever, anorexia, thrombocytopenia, anemia, granulocytopenia, diarrhea, asthenia, abdominal pain, headache, alopecia, and somnolence.

CNS Activity

Originator

Approval Year

1987
121
Targets

Targets

Primary TargetPharmacologyConditionPotency
Binding Agent
1076
Binding Agent
1076
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
Approved
8583
MESNEX

Approved Use

Mesna Injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. Limitation of Use: Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. Mesna Injection is a cytoprotective agent indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. (1) Limitation of Use: Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. (1)

Launch Date

1988
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
511 μM
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/8462128
1.2 g single, intravenous
dose: 1.2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MESNA plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
33 μM
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/8462128
1.2 g single, oral
dose: 1.2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESNA plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
79 μM
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/9469350
0.24 g/m² single, intravenous
dose: 0.24 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
201 μM × h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/8462128
1.2 g single, intravenous
dose: 1.2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MESNA plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
110 μM × h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/8462128
1.2 g single, oral
dose: 1.2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESNA plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
49 μM × h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/9469350
0.24 g/m² single, intravenous
dose: 0.24 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
92 min
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/9469350
0.24 g/m² single, intravenous
dose: 0.24 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Other AEs: Headache, Hypoaesthesia...
Other AEs:
Headache (43.8%)
Hypoaesthesia (0%)
Malaise (0%)
Myalgia (0%)
Nausea (0%)
Pharyngitis (0%)
Somnolence (6.3%)
Upper respiratory infection (0%)
Vomiting (0%)
Dizziness (6.3%)
Abdominal pain (6.3%)
Coughing (0%)
Diarrhea (6.3%)
Anorexia (0%)
Flushing (12.5%)
Injection site reaction (12.5%)
Back pain (6.3%)
Dyspepsia (12.5%)
Paraesthesia (6.3%)
Renal pain (6.3%)
Rigors (12.5%)
Fatigue (0%)
Conjunctivitis (6.3%)
Arthralgia (12.5%)
Application site reaction (31.3%)
Photophobia (18.8%)
Dehydration (6.3%)
Dysuria (6.3%)
Sweating increased (6.3%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Other AEs: Headache, Hypoaesthesia...
Other AEs:
Headache (33.3%)
Hypoaesthesia (0%)
Malaise (8.3%)
Myalgia (0%)
Nausea (16.7%)
Pharyngitis (0%)
Somnolence (8.3%)
Upper respiratory infection (0%)
Vomiting (16.7%)
Dizziness (8.3%)
Abdominal pain (8.3%)
Coughing (0%)
Diarrhea (0%)
Anorexia (8.3%)
Flushing (0%)
Injection site reaction (0%)
Back pain (0%)
Dyspepsia (0%)
Paraesthesia (8.3%)
Renal pain (0%)
Rigors (0%)
Fatigue (8.3%)
Conjunctivitis (0%)
Arthralgia (0%)
Application site reaction (0%)
Photophobia (0%)
Dehydration (0%)
Dysuria (0%)
Sweating increased (0%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
AEs

AEs

AESignificanceDosePopulation
Anorexia 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Coughing 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Fatigue 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Hypoaesthesia 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Malaise 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Myalgia 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Nausea 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Pharyngitis 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Upper respiratory infection 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Vomiting 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Arthralgia 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dyspepsia 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Flushing 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Injection site reaction 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Rigors 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Photophobia 18.8%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Application site reaction 31.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Headache 43.8%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Abdominal pain 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Back pain 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Conjunctivitis 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dehydration 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Diarrhea 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dizziness 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dysuria 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Paraesthesia 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Renal pain 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Somnolence 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Sweating increased 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Application site reaction 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Arthralgia 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Back pain 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Conjunctivitis 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Coughing 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dehydration 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Diarrhea 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dyspepsia 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dysuria 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Flushing 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Hypoaesthesia 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Injection site reaction 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Myalgia 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Pharyngitis 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Photophobia 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Renal pain 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Rigors 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Sweating increased 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Upper respiratory infection 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Nausea 16.7%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Vomiting 16.7%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Headache 33.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Abdominal pain 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Anorexia 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dizziness 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Fatigue 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Malaise 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Paraesthesia 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Somnolence 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
MATE1
182

MRP2
252

P-gp
2052
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
MATE1
182
 yes
MRP2
252
 yes
P-gp
2052
 yes
PubMed

PubMed

TitleDatePubMed
The cytogenetic action of ifosfamide, mesna, and their combination on peripheral rabbit lymphocytes: an in vivo/in vitro cytogenetic study.
2014-10
Comparision of uroprotective activity of reduced glutathione with mesna in ifosfamide induced hemorrhagic cystitis in rats.
2013-07-01
Surface functionalities of gold nanoparticles impact embryonic gene expression responses.
2013-03
Acrolein and chloroacetaldehyde: an examination of the cell and cell-free biomarkers of toxicity.
2013-02-25
Combined intravenous and oral mesna in outpatients treated with ifosfamide.
1997
Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide.
1997
Ifosfamide encephalopathy and methylene-blue: a case report.
1996-08
Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
1996-06
[The prevention of hemorrhagic cystitis during the performance of bone marrow and peripheral blood stem cell transplantation in the hematologic cancer clinic].
1996
[Ifosfamide-induced hemorrhagic cystitis and its prevention by mesna].
1995-06
[Epileptic seizures and treatment with ifosfamide-mesna].
1994
Encephalopathy with hyponatremia and inappropriate arginine vasopressin secretion following an intravenous ifosfamide infusion.
1990
Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.
1989-07
Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide. An experimental study/short communication.
1989-06
Treatment of gynecological adenocarcinomas with a combination of ifosfamide, adriamycin and cisplatin.
1988-05
[Encephalopathy caused by an ifosfamide-mesna combination].
1988-04-02
Efficacy of mesna in preventing further cyclophosphamide-induced hemorrhagic cystitis.
1988
Ifosfamide/mesna related encephalopathy: a case report with a possible role of phenobarbital in enhancing neurotoxicity.
1988
Irreversible encephalopathy with ifosfamide/mesna.
1987-08
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
1987-08
The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
1987-05
Ifosfamide/mesna encephalopathy.
1987-04-25
Ifosfamide neurotoxicity in children.
1987-03
Encephalopathy with rapid infusion ifosfamide/mesna.
1987-02-14
Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna.
1987-02
Blurring of vision due to ifosfamide.
1987
Electron microscopic investigations of the cyclophosphamide-induced lesions of the urinary bladder of the rat and their prevention by mesna.
1987
Avoiding ifosfamide/mesna encephalopathy.
1986-08-16
Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna.
1986-08
Prediction of ifosfamide/mesna associated encephalopathy.
1986-07
The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial.
1986-06
Phase II study of ifosfamide in cervical cancer.
1986-06
Cause and prevention of mafosfamide-induced venous pain.
1986
Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.
1986
CNS-side effects induced by Ifosfamide-Mesna in children with osteosarcomas.
1986
Ifosfamide, mesna, and encephalopathy.
1985-06-15
Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma.
1985-05
Ifosfamide/mesa and encephalopathy.
1985-03-30
Encephalopathy associated with ifosphamide/mesna therapy.
1985-02-16
Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study.
1984-12
[Prevention of tumor formation in the bladder by sodium-2-mercaptoethane sulfonate (mesna). Experimental studies and clinical consequences].
1984-09
Prevention of cyclophosphamide cystitis with 2-mercaptoethane sodium sulfonate: a histologic study.
1984-09
The use of sodium 2-mercaptoethane sulfonate to prevent cyclophosphamide cystitis.
1984-05
Prevention of cyclophosphamide-induced carcinogenesis in the urinary bladder of rats by administration of mesna.
1983-09
Experience with mesna in patients receiving allogeneic bone marrow transplants for poor prognostic leukaemia.
1983-09
Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna).
1983-02-15
Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.
1983-02
Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.
1982
Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds.
1981
Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.
1980-09-27
Patents

Patents

05155108
3
05202324
2
07517996
3

Sample Use Guides

In Vivo Use Guide
240 mg/m2 every 4 hours (injection) or 240 mg/m2 (first point, injection) following with 480 mg/m2 (2 and 6 hours, oral).
Route of Administration: Other
In Vitro Use Guide
Unknown
Name Type Language
2-MERCAPTOETHANESULFONIC ACID
Systematic Name English
COENZYME M
Preferred Name English
MESNA FREE ACID
Common Name English
.BETA.-MERCAPTOETHANESULFONIC ACID
Systematic Name English
MERCAPTOETHANESULFONIC ACID
Systematic Name English
Classification Tree Code System Code
NDF-RT N0000180854
Created by admin on Mon Mar 31 18:15:18 GMT 2025 , Edited by admin on Mon Mar 31 18:15:18 GMT 2025
Code System Code Type Description
WIKIPEDIA
Mercaptoethanesulfonic acid
Created by admin on Mon Mar 31 18:15:18 GMT 2025 , Edited by admin on Mon Mar 31 18:15:18 GMT 2025
PRIMARY
FDA UNII
VHD28S0H7F
Created by admin on Mon Mar 31 18:15:18 GMT 2025 , Edited by admin on Mon Mar 31 18:15:18 GMT 2025
PRIMARY
EVMPD
SUB32737
Created by admin on Mon Mar 31 18:15:18 GMT 2025 , Edited by admin on Mon Mar 31 18:15:18 GMT 2025
PRIMARY
DAILYMED
VHD28S0H7F
Created by admin on Mon Mar 31 18:15:18 GMT 2025 , Edited by admin on Mon Mar 31 18:15:18 GMT 2025
PRIMARY
CHEBI
17905
Created by admin on Mon Mar 31 18:15:18 GMT 2025 , Edited by admin on Mon Mar 31 18:15:18 GMT 2025
PRIMARY
CHEBI
58319
Created by admin on Mon Mar 31 18:15:18 GMT 2025 , Edited by admin on Mon Mar 31 18:15:18 GMT 2025
PRIMARY
EPA CompTox
DTXSID8023264
Created by admin on Mon Mar 31 18:15:18 GMT 2025 , Edited by admin on Mon Mar 31 18:15:18 GMT 2025
PRIMARY
SMS_ID
100000126313
Created by admin on Mon Mar 31 18:15:18 GMT 2025 , Edited by admin on Mon Mar 31 18:15:18 GMT 2025
PRIMARY
ECHA (EC/EINECS)
222-167-0
Created by admin on Mon Mar 31 18:15:18 GMT 2025 , Edited by admin on Mon Mar 31 18:15:18 GMT 2025
PRIMARY
PUBCHEM
598
Created by admin on Mon Mar 31 18:15:18 GMT 2025 , Edited by admin on Mon Mar 31 18:15:18 GMT 2025
PRIMARY
CAS
3375-50-6
Created by admin on Mon Mar 31 18:15:18 GMT 2025 , Edited by admin on Mon Mar 31 18:15:18 GMT 2025
PRIMARY
RXCUI
1546354
Created by admin on Mon Mar 31 18:15:18 GMT 2025 , Edited by admin on Mon Mar 31 18:15:18 GMT 2025
PRIMARY RxNorm
DRUG BANK
DB09110
Created by admin on Mon Mar 31 18:15:18 GMT 2025 , Edited by admin on Mon Mar 31 18:15:18 GMT 2025
PRIMARY
METABOLITE INACTIVE (PARENT)
Structure of 2,2'-DITHIODIETHANESULFONIC ACID
SALT/SOLVATE (PARENT)
Structure of MESNA
SALT/SOLVATE (PARENT)
Structure of ARGIMESNA
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966